News
Intel has stood by Tan, and in a statement told The Wall Street Journal that its board and management were aligned on strategy. Before Trump jumped into the fray, Tan was already at odds with some of ...
Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...
American shoppers hit with 60% of costs as import taxes reach 100-year high - Tariffs on U.S. trading partners finally in ...
The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...
Former Gov. Andrew M. Cuomo acknowledged that he had not run an effective race in the mayoral primary and asked for ...
From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.
AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...
President Trump threatened 250% tariffs on pharma; Pfizer CEO contacted Trump about most favored nation pricing; Ex-X CEO joins eMed.
Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.
Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...
The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...
‘We will work collaboratively’: Big Pharma admits it is discussing Trump’s plan to lower drug prices
Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results